PARPi potentiates with current conventional therapy in MLL leukemia

References

• Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96:24-33; PMID:10891426
   PubMed Web of Science ®Google Scholar
• Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87:2870-7; PMID:8639906
   PubMed Web of Science ®Google Scholar
• Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW. SnapShot: Acute myeloid leukemia. Cancer Cell 2012; 22:698-8 e691; http://dx.doi.org/10.1016/j.ccr.2012.10.017
   PubMedGoogle Scholar
• Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964; 20:202-3; PMID:5322617; http://dx.doi.org/10.1007/BF02135399
   PubMedGoogle Scholar
• Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20:85-93; PMID:6156004; http://dx.doi.org/10.1016/0092-8674(80)90237-8
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429-40; PMID:12011120; http://dx.doi.org/10.1200/JCO.2002.04.117
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-803; PMID:16532500; http://dx.doi.org/10.1002/cncr.21792
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54; PMID:14627790; http://dx.doi.org/10.1056/NEJMra023075
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015; 162:974-86; PMID:26317466; http://dx.doi.org/10.1016/j.cell.2015.07.011
   PubMed Web of Science ®Google Scholar
• Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015; 162:961-73; PMID:26317465; http://dx.doi.org/10.1016/j.cell.2015.07.056
   PubMed Web of Science ®Google Scholar
• Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994; 91:11797-801; PMID:7527544; http://dx.doi.org/10.1073/pnas.91.25.11797
   PubMed Web of Science ®Google Scholar
• Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010; 35:208-19; PMID:20106667; http://dx.doi.org/10.1016/j.tibs.2009.12.003
   PubMed Web of Science ®Google Scholar
• Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JA, Larsen AK, Saffi J. PARPs and the DNA damage response. Carcinogenesis 2012; 33:1433-40; PMID:22431722; http://dx.doi.org/10.1093/carcin/bgs132
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang F, Tang T, Guo C. The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med 2012; 6:156-64; PMID:22660976; http://dx.doi.org/10.1007/s11684-012-0197-3
   PubMedGoogle Scholar
• Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39:8-24; PMID:20603072; http://dx.doi.org/10.1016/j.molcel.2010.06.017
   PubMed Web of Science ®Google Scholar
• Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12:68-78; http://dx.doi.org/10.1038/nrc3181
   PubMed Web of Science ®Google Scholar
• Carreira A, Hilario J, Amitani I, Baskin RJ, Shivji MK, Venkitaraman AR, Kowalczykowski S, et al. The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 2009; 136:1032-43; PMID:19303847; http://dx.doi.org/10.1016/j.cell.2009.02.019
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892-6
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204; PMID:18256616; http://dx.doi.org/10.1038/nrc2342
   PubMed Web of Science ®Google Scholar
• Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, Gil J, Leung AY, Ashworth A, So CW, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med 2015; 21:1481-90; PMID:26594843; http://dx.doi.org/10.1038/nm.3993
   PubMed Web of Science ®Google Scholar
• Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, et al. The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. Mol Cancer Ther 2015; 14:889-98; PMID:25667168; http://dx.doi.org/10.1158/1535-7163.MCT-14-0276
   PubMed Web of Science ®Google Scholar
• Orta ML, Höglund A, Calderón-Montaño JM, Domínguez I, Burgos-Morón E, Visnes T, Pastor N, Ström C, López-lázaro M, Helleday T, et al. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions. Nucleic Acids Res 2014; 42:9108-20; PMID:25074383; http://dx.doi.org/10.1093/nar/gku638
   PubMed Web of Science ®Google Scholar
• Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, et al. BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta 2015; 1852:462-72; http://dx.doi.org/10.1016/j.bbadis.2014.12.001
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301; PMID:20200537; http://dx.doi.org/10.1038/nrc2812
   PubMed Web of Science ®Google Scholar
• Zhao L, So CW. PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment. Experimental hematology 2016; 44:902-7; PMID:27473567; http://dx.doi.org/10.1016/j.exphem.2016.07.007
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Rüter B, Marks R, Claus R, Wäsch R, Finke J. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009; 44:585-8; PMID:19363531; http://dx.doi.org/10.1038/bmt.2009.64
   PubMed Web of Science ®Google Scholar
• Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24:679-86; PMID:20130602; http://dx.doi.org/10.1038/leu.2010.6
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Cogger VC, Muller M, Le Couteur DG. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 2004; 32:794-9; PMID:15258103; http://dx.doi.org/10.1124/dmd.32.8.794
   PubMed Web of Science ®Google Scholar
• Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53:209-19; PMID:14610616; http://dx.doi.org/10.1007/s00280-003-0726-5
   PubMed Web of Science ®Google Scholar
• Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22:9063-74; PMID:14663485; http://dx.doi.org/10.1038/sj.onc.1207229
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013; 12:877-83; PMID:23428903; http://dx.doi.org/10.4161/cc.24034
   PubMed Web of Science ®Google Scholar
• Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, et al. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013; 98:1397-406; PMID:23349304; http://dx.doi.org/10.3324/haematol.2012.079251
   PubMed Web of Science ®Google Scholar
• Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011; 3:257-67; PMID:22084640; http://dx.doi.org/10.1177/1758834011417039
   PubMedGoogle Scholar
• Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8:2232-42; PMID:19671751; http://dx.doi.org/10.1158/1535-7163.MCT-09-0142
   PubMed Web of Science ®Google Scholar
• Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer 2014; 111:1319-26; PMID:25003660; http://dx.doi.org/10.1038/bjc.2014.378
   PubMed Web of Science ®Google Scholar
• Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991; 37:223-27; PMID:1907096; http://dx.doi.org/10.1002/ajh.2830370402
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21:5483-95; PMID:12154409; http://dx.doi.org/10.1038/sj.onc.1205699
   PubMed Web of Science ®Google Scholar
• Michel B, Flores MJ, Viguera E, Grompone G, Seigneur M, Bidnenko V. Rescue of arrested replication forks by homologous recombination. Proc Natl Acad Sci U S A 2001; 98:8181-8; PMID:11459951; http://dx.doi.org/10.1073/pnas.111008798
   PubMed Web of Science ®Google Scholar
• McGlynn P, Lloyd RG. Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol 2002; 3:859-70; PMID:12415303; http://dx.doi.org/10.1038/nrm951
   PubMed Web of Science ®Google Scholar
• Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007; 6:1718-27; PMID:17575103; http://dx.doi.org/10.1158/1535-7163.MCT-07-0010
   PubMed Web of Science ®Google Scholar
• Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 1983; 258:15365-70; PMID:6317692
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-41; PMID:10075079; http://dx.doi.org/10.1016/S0006-2952(98)00307-4
   PubMed Web of Science ®Google Scholar
• Di Marco A, Silvestrini R, Di Marco S, Dasdia T. Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells. J Cell Biol 1965; 27:545-50; PMID:5885429; http://dx.doi.org/10.1083/jcb.27.3.545
   PubMed Web of Science ®Google Scholar
• Munger C, Ellis A, Woods K, Randolph J, Yanovich S, Gewirtz D. Evidence for inhibition of growth related to compromised DNA synthesis in the interaction of daunorubicin with H-35 rat hepatoma. Cancer Res 1988; 48:2404-11; PMID:3356005
   PubMed Web of Science ®Google Scholar
• Feinstein E, Canaani E, Weiner LM. Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry 1993; 32:13156-161; PMID:7694653; http://dx.doi.org/10.1021/bi00211a026
   PubMed Web of Science ®Google Scholar
• Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005; 57:73-81; PMID:16036566; http://dx.doi.org/10.1080/15216540500079093
   PubMed Web of Science ®Google Scholar